Jump to content

A monthly injection could enable severe asthma patients to stop taking daily steroid tablets without affecting their symptoms, a new trial has found.

The drug, Tezepelumab (also known as Tezspir and made by AstraZeneca), works by binding to and blocking a protein that drives airway inflammation.

The injection is recommended as an additional maintenance treatment for patients over 12 when usual medications have not proven effective enough.

It was approved for NHS use by the National Institute for Health and Care Excellence (NICE) in 2023.

Read full article.

Source: The Independent, 27 November 2025.

0 Comments


Recommended Comments

There are no comments to display.


Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.